Fertility Treatment Cost: What Insurance Misses

A single IVF cycle costs between $15,000 and $30,000 fully loaded — and only 27% of large employers covered it in 2024, according to the Kaiser Family Foundation (KFF) Employer Health Benefits Survey. For a $200,000 household running two cycles, that’s a potential $60,000 out-of-pocket exposure that no amount of premium health insurance automatically eliminates.

This is not a coverage gap that resolves itself at higher income levels. The data show that $150k+ households face the same structural exclusions as everyone else — ERISA preemption, mandate carve-outs for self-insured plans, and medication costs that most plans treat as non-covered regardless of state law. What changes at higher incomes is the ability to absorb the hit, not the size of the hit.

Key Numbers at a Glance

Sources: KFF Employer Health Benefits Survey 2024; IRS Publication 969 (2025); FertilityIQ; GoodRx; CNY Fertility; Advanced Fertility Center; Carrot Fertility. All figures reflect 2024–2025 unless otherwise noted.

The Coverage Illusion: State Mandates and the ERISA Wall

As of December 1, 2025, 25 states plus Washington D.C. have passed fertility insurance coverage laws, with 15 of those laws including IVF coverage to some degree, according to RESOLVE: The National Infertility Association. That sounds like meaningful progress. The catch is structural and large: approximately 67% of covered workers in employer-sponsored plans are enrolled in self-insured arrangements, per KFF data — and self-insured plans are fully exempt from state mandates under ERISA federal preemption.

The practical implication: if your employer self-insures, which most large employers do, your state’s IVF mandate is legally irrelevant to your plan. A high-earning household in Massachusetts — one of the oldest mandate states — employed at a Fortune 500 company running a self-insured plan gets no statutory IVF coverage protection. The mandate simply does not apply. Research published in the Journal of Assisted Reproduction and Genetics (2025) found that even in states with comprehensive IVF mandates, only 41% of self-insured employers in those states voluntarily covered IVF.

Mandate carve-outs compound this. California’s SB 729 — which took effect January 1, 2026 for most plans — applies only to fully insured large-group plans with 100 or more employees. Small-group plans must offer coverage but are not required to include IVF. Religious employer exemptions exist across most mandate states. And even where coverage exists, plans frequently impose lifetime dollar caps or cycle limits that make the math less favorable than the headline coverage suggests.

The employer voluntary coverage picture has improved, but still leaves most workers exposed. According to Mercer data cited by IVF Pharmacy (2026), 61% of companies with 500 or more employees now offer some form of fertility benefit — up from 30% in 2020 among all employers. KFF’s 2024 survey found 27% of large companies covered IVF specifically. That gap between “fertility benefit” and “IVF coverage” matters: many employer plans cover diagnostics and IUI while explicitly excluding IVF procedures and associated medications.

The Real Cost Stack: What a Single Cycle Actually Costs

Clinic websites advertising $10,000–$12,000 IVF cycles are not lying — they are presenting the base procedural fee, which excludes the majority of what patients actually pay. The American Society for Reproductive Medicine (ASRM) reports an average base cycle cost of approximately $12,400 for the core clinic fee (egg retrieval, embryo creation, and transfer), but that figure excludes medications, genetic testing, and frozen embryo transfers — all of which most treatment pathways require.

Building out the real cost stack for a single complete cycle with standard add-ons:

Sources: ASRM via GoodRx (2024); FertilityIQ (2024); CNY Fertility (2025–2026); Carrot Fertility (2025–2026); Illume Fertility (2025). Range reflects national variation; major metro markets trend toward the high end.

Fertility medications deserve particular scrutiny. According to Drug Topics (April 2026), the cost of IVF medications has risen 84% over the past decade, far outpacing the 37% average list price increase across all prescription drugs per the GoodRx List Price Index. Injectable gonadotropins — Gonal-F, Follistim, Menopur — are the primary cost drivers, and they are frequently excluded from coverage even in plans that nominally cover IVF procedures. A patient can have IVF “covered” and still face a $5,000 out-of-pocket medication bill for a single cycle.

Multiple Cycles: Where the Exposure Gets Serious

Success rates — which the CDC and SART track through annual reporting — vary dramatically by age. Live birth rates per embryo transfer using a patient’s own eggs fall from roughly 40%–50% for women under 35 to below 20% for women over 40, based on data available through the most recent SART reporting periods. That probability structure means multiple cycles are statistically common, not exceptional. A Journal of Urology study found that out-of-pocket IVF costs averaged around $19,000 per cycle for patients who reached that stage, with each additional cycle running approximately $7,000 in marginal cost (reflecting reuse of frozen embryos rather than a full fresh retrieval).

For a household running two full fresh cycles plus two frozen embryo transfers — a realistic multi-cycle scenario for women in their late 30s — the cumulative out-of-pocket exposure before any insurance offset ranges from approximately $44,000 to $85,000. At $200,000 gross household income, the upper end of that range represents 42.5% of pre-tax earnings.

Sources: FertilityIQ (2024); Journal of Urology study via cofertility.com; Illume Fertility (2025–2026); CNY Fertility (2025–2026). Ranges reflect national self-pay rates; individual costs vary by clinic and protocol.

Finluxy Healthcare Spend Index: Fertility Treatment Scenarios

The Finluxy Healthcare Spend Index measures annual out-of-pocket healthcare spend (excluding premiums) as a percentage of gross household income. The formula: OOP spend ÷ gross income × 100. The KFF benchmark for $150k+ households is 1.2%–2.5% of gross income in a typical year.

Fertility treatment blows through that benchmark in a single treatment year — often by a factor of three to five. The table below models the index for a $200,000 household across three treatment scenarios.

Index calculated using Finluxy Healthcare Spend Index methodology: OOP spend ÷ gross income × 100. KFF benchmark 1.2%–2.5% for $150k+ households per Cluster Brief. OOP ranges sourced from FertilityIQ, CNY Fertility, and Advanced Fertility Center (2025–2026). Gross income: $200,000.

These figures exclude other annual out-of-pocket healthcare costs — deductibles, specialist visits, prescription copays — that a household also carries during a fertility treatment year. A couple simultaneously managing a chronic condition or running through an out-of-pocket maximum on their primary health plan could see the Finluxy Healthcare Spend Index approach 50% of gross income in a worst-case treatment year. That number belongs in a liquidity plan, not just a healthcare budget.

The Overlooked Cost: PGT-A and What Insurance Refuses to Cover

The most coverage-resistant line item in the fertility cost stack is preimplantation genetic testing for aneuploidy (PGT-A). Even patients with generous IVF coverage routinely discover that PGT-A is carved out entirely. FertilityIQ notes that PGT-A typically costs around $5,000 per IVF cycle in the United States and accounts for 20%–30% of overall treatment costs — and it is “almost always excluded” even for patients whose insurance covers IVF procedures.

This matters disproportionately to older patients. PGT-A screens embryos for chromosomal abnormalities before transfer, increasing the probability of live birth per transfer and reducing miscarriage risk. For a woman over 37, where aneuploid rates in embryos are substantially higher, skipping PGT-A to save $5,000 can lead to failed transfers and additional retrieval cycles costing $15,000–$30,000 each. The insurance structure creates a perverse incentive: denying coverage for the test that reduces the total number of costly treatment cycles needed.

Similarly, the mental health coverage gap in standard employer plans intersects here in an underappreciated way. Fertility treatment carries significant psychological burden — anxiety, depression, and grief from failed cycles — yet the mental health support that patients typically need during IVF is subject to the same coverage gaps and out-of-network rate structures that affect all mental health services.

HSA Optimization: The Triple Tax Strategy Applied to Fertility Costs

A health savings account (HSA) is the most tax-efficient vehicle for covering IVF costs — and most households in this income bracket underutilize it during fertility treatment years. The triple tax benefit is real: contributions are pre-tax, growth is tax-free, and qualified withdrawals are tax-free. For a $150k+ household in the 32%–37% federal marginal bracket, the tax efficiency on HSA spending is meaningful.

For 2025, the IRS set HSA contribution limits at $4,300 for individual coverage and $8,550 for family coverage (IRS Publication 969, 2025). The 2026 limits hold steady at $4,400 individual and $8,750 family, confirmed by both IRS Publication 969 and Congress.gov. A catch-up contribution of $1,000 is available for account holders age 55 and older, applicable to both years.

IVF procedures, medications, egg retrieval, embryo transfers, and most associated diagnostic testing qualify as HSA-eligible medical expenses under IRS rules. Long-term embryo storage fees may not qualify — confirm with your HSA administrator before allocating funds. At 32% effective federal tax rate plus state income tax, an $8,550 family HSA contribution generates approximately $2,736–$3,250 in combined federal and state tax savings in a high-tax state, effectively reducing the real cost of fertility treatment by that amount. Against a $25,000–$40,000 treatment year, that is material but not transformative.

For a deeper analysis of how HSA investment compounding affects long-term healthcare costs, see HSA maximization over a 10-year horizon. The more relevant optimization during active fertility treatment is to front-load HSA contributions at the start of the year before treatment begins — capturing the full year’s deductibility before the first bill arrives. Coordinating this with an HSA-eligible high-deductible plan versus a PPO requires modeling whether the premium savings from the HDHP offset the higher deductible during a year with predictably high medical spending.

Source: IRS Publication 969 (2025); IRS 2025 tax bracket tables. California HSA non-conformity per California Franchise Tax Board guidance — California taxes HSA contributions and earnings as ordinary income.

What the Data Shows That Most Coverage Overlooks

The standard narrative treats the ERISA self-insured exemption as a technicality that primarily harms lower-income workers. The data does not support that framing. High earners at large self-insured employers — the exact demographic most likely to be earning $150k+ — face the same mandate exclusion. A senior director at a major tech firm, a partner at a professional services firm, an executive at a self-insured Fortune 500 company: none of them are reached by state IVF mandates unless their employer voluntarily opts in.

KFF’s 2024 data shows that 27% of large employers covered IVF specifically. That means 73% of large employers did not. Among all employers, 42% offered some fertility benefit — but that figure collapses when restricted to IVF coverage alone, which requires the full procedure, not just diagnostics or IUI. The 12% cost-barrier figure from KFF’s 2024 research (reproductive-age women who cited cost as the primary reason they did not receive needed fertility services) likely understates the true impact among households who did seek treatment but carried the cost themselves without insurance support.

For households tracking annual healthcare spend at $150k+, fertility treatment represents a structurally different category than chronic condition management or routine care. It is concentrated, time-limited, and largely uninsured — which makes it the most significant single-year healthcare cost exposure most high-earning households will face outside of a major acute illness. For related context on how total out-of-pocket exposure benchmarks against income, see the out-of-pocket healthcare cost analysis at $200k income.

Practical Framework for $150k+ Households

Before a first cycle begins, two financial decisions materially affect total out-of-pocket cost: plan selection and employer benefit verification. On plan selection — if treatment will occur in a calendar year, modeling employer health insurance employee cost against the out-of-pocket maximum is essential. A plan with a $3,000 family out-of-pocket maximum that covers IVF procedures — even partially — is structurally superior to a plan that excludes fertility treatment regardless of how competitive its premium looks. See the out-of-pocket maximum reality analysis for how deductible timing affects single-year exposure.

On employer benefit verification: “fertility benefit” language in summary plan documents is not equivalent to IVF coverage. Ask HR explicitly whether the plan covers IVF procedures, injectable fertility medications separately, PGT-A, and frozen embryo transfers — and at what lifetime dollar or cycle limit. The gap between those four line items and a generic “fertility benefit” can easily exceed $20,000 per cycle.

For households evaluating whether a premium concierge or executive health relationship changes the fertility care calculus, it largely does not — concierge medicine retainers cover primary care coordination, not reproductive endocrinology. The concierge medicine cost analysis and the executive health program cost benchmark clarify what those models cover and where specialty care costs remain fully out-of-pocket. The premium healthcare cost guide for $150k+ households provides the broader annual TCO framework into which fertility costs slot as a major variable expense line.

Finally, geography matters in a way that goes beyond clinic pricing. Households in states with comprehensive IVF mandates who are enrolled in fully insured employer plans — not self-insured — hold the one structural advantage in this cost analysis. Verifying your plan type is a 10-minute HR conversation that could determine whether you face $0 or $30,000 in out-of-pocket costs for the same clinical pathway. That asymmetry is worth a phone call before any cycle begins. For comparison of how direct primary care models handle ongoing primary care costs during treatment years, see direct primary care versus insurance annual math.